{"transactions":[{"id":3130,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-09-03T21:18:14.000Z","date":"2026-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":2528,"price":7.1439,"value":18059.7792,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":196060,"source":{"system":"sec-edgar","filing":"0001873392-26-000006","document":"wk-form4_1788470291.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000006/wk-form4_1788470291.xml","form_type":"4"}},{"id":794602,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T23:24:16.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option fully vested on November 4, 2023."}],"balance_after":49831,"derivative":{"exercise_price":1.74,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001873392-26-000004","document":"wk-form4_1777937054.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000004/wk-form4_1777937054.xml","form_type":"4"}},{"id":794601,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-05-04T23:24:16.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":15.3302,"value":229953.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":198588,"source":{"system":"sec-edgar","filing":"0001873392-26-000004","document":"wk-form4_1777937054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000004/wk-form4_1777937054.xml","form_type":"4"}},{"id":794600,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-05-04T23:24:16.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":1.74,"value":26100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."}],"balance_after":213588,"source":{"system":"sec-edgar","filing":"0001873392-26-000004","document":"wk-form4_1777937054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000004/wk-form4_1777937054.xml","form_type":"4"}},{"id":849646,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-11T20:35:13.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":11894,"price":13.0476,"value":155188.1544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":198588,"source":{"system":"sec-edgar","filing":"0001873392-26-000002","document":"wk-form4_1773261310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000002/wk-form4_1773261310.xml","form_type":"4"}},{"id":849645,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-11T20:35:13.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":3116,"price":13.024,"value":40582.784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":210482,"source":{"system":"sec-edgar","filing":"0001873392-26-000002","document":"wk-form4_1773261310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000002/wk-form4_1773261310.xml","form_type":"4"}},{"id":871295,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T23:19:52.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":83200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030."}],"balance_after":83200,"derivative":{"exercise_price":11.93,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":83200},"source":{"system":"sec-edgar","filing":"0001873392-26-000001","document":"wk-form4_1772579989.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000001/wk-form4_1772579989.xml","form_type":"4"}},{"id":871294,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-03T23:19:52.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":14038,"price":11.7564,"value":165036.3432,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":213598,"source":{"system":"sec-edgar","filing":"0001873392-26-000001","document":"wk-form4_1772579989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000001/wk-form4_1772579989.xml","form_type":"4"}},{"id":871293,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-03T23:19:52.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":7223,"price":11.6579,"value":84205.0117,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":227636,"source":{"system":"sec-edgar","filing":"0001873392-26-000001","document":"wk-form4_1772579989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000001/wk-form4_1772579989.xml","form_type":"4"}},{"id":871292,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-03T23:19:52.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":55800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":234859,"source":{"system":"sec-edgar","filing":"0001873392-26-000001","document":"wk-form4_1772579989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000001/wk-form4_1772579989.xml","form_type":"4"}},{"id":1048792,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2025-09-04T21:03:44.000Z","date":"2025-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":1746,"price":5.4302,"value":9481.1292,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":179059,"source":{"system":"sec-edgar","filing":"0001873392-25-000003","document":"wk-form4_1757019821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339225000003/wk-form4_1757019821.xml","form_type":"4"}},{"id":1232454,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:59:15.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":90800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the option shares shall vest and become exercisable on March 1, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2029."}],"balance_after":90800,"derivative":{"exercise_price":11.94,"expiration_date":"2035-03-01","underlying":"Common Stock","underlying_shares":90800},"source":{"system":"sec-edgar","filing":"0001689375-25-000013","document":"wk-form4_1741125544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937525000013/wk-form4_1741125544.xml","form_type":"4"}},{"id":1232453,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2025-03-04T21:59:15.000Z","date":"2025-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":5144,"price":11.6786,"value":60074.7184,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":180805,"source":{"system":"sec-edgar","filing":"0001689375-25-000013","document":"wk-form4_1741125544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937525000013/wk-form4_1741125544.xml","form_type":"4"}},{"id":1232452,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2025-03-04T21:59:15.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":60800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":185949,"source":{"system":"sec-edgar","filing":"0001689375-25-000013","document":"wk-form4_1741125544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937525000013/wk-form4_1741125544.xml","form_type":"4"}},{"id":1398202,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-09-30T20:32:11.000Z","date":"2024-09-26","kind":"sale","planned":true,"acquired":false,"shares":847,"price":16,"value":13552.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024."}],"balance_after":125149,"source":{"system":"sec-edgar","filing":"0001689375-24-000056","document":"wk-form4_1727728325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000056/wk-form4_1727728325.xml","form_type":"4"}},{"id":1411433,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-09-10T20:33:34.000Z","date":"2024-09-09","kind":"sale","planned":true,"acquired":false,"shares":1904,"price":15.0684,"value":28690.2336,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":125996,"source":{"system":"sec-edgar","filing":"0001689375-24-000054","document":"wk-form4_1726000407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000054/wk-form4_1726000407.xml","form_type":"4"}},{"id":1411432,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-09-10T20:33:34.000Z","date":"2024-09-06","kind":"sale","planned":true,"acquired":false,"shares":399,"price":15.1947,"value":6062.6853,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.07 to $15.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":127900,"source":{"system":"sec-edgar","filing":"0001689375-24-000054","document":"wk-form4_1726000407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000054/wk-form4_1726000407.xml","form_type":"4"}},{"id":1414663,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-09-05T22:48:42.000Z","date":"2024-09-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":171,"price":15.126,"value":2586.546,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.  The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":128299,"source":{"system":"sec-edgar","filing":"0001689375-24-000051","document":"wk-form4_1725576514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000051/wk-form4_1725576514.xml","form_type":"4"}},{"id":1414662,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-09-05T22:48:42.000Z","date":"2024-09-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":983,"price":15.4234,"value":15161.2022,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.  The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $15.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":128470,"source":{"system":"sec-edgar","filing":"0001689375-24-000051","document":"wk-form4_1725576514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000051/wk-form4_1725576514.xml","form_type":"4"}},{"id":1414661,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-09-05T22:48:42.000Z","date":"2024-09-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":15,"price":17.702,"value":265.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.  The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":129453,"source":{"system":"sec-edgar","filing":"0001689375-24-000051","document":"wk-form4_1725576514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000051/wk-form4_1725576514.xml","form_type":"4"}},{"id":1414660,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-09-05T22:48:42.000Z","date":"2024-09-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":156,"price":16.9255,"value":2640.378,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.  The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.49 to $17.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":129468,"source":{"system":"sec-edgar","filing":"0001689375-24-000051","document":"wk-form4_1725576514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000051/wk-form4_1725576514.xml","form_type":"4"}},{"id":1414659,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-09-05T22:48:42.000Z","date":"2024-09-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":483,"price":15.7611,"value":7612.6113,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.  The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.49 to $16.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":129624,"source":{"system":"sec-edgar","filing":"0001689375-24-000051","document":"wk-form4_1725576514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000051/wk-form4_1725576514.xml","form_type":"4"}},{"id":1428316,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T20:33:43.000Z","date":"2024-08-16","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the option shares shall vest and become exercisable on November 4, 2020, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":64831,"derivative":{"exercise_price":1.74,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001689375-24-000048","document":"wk-form4_1724186017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000048/wk-form4_1724186017.xml","form_type":"4"}},{"id":1428315,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-08-20T20:33:43.000Z","date":"2024-08-16","kind":"sale","planned":true,"acquired":false,"shares":502,"price":16.698,"value":8382.396,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.69 to $16.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":130107,"source":{"system":"sec-edgar","filing":"0001689375-24-000048","document":"wk-form4_1724186017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000048/wk-form4_1724186017.xml","form_type":"4"}},{"id":1428314,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-08-20T20:33:43.000Z","date":"2024-08-16","kind":"sale","planned":true,"acquired":false,"shares":26595,"price":16.2594,"value":432418.743,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.67 to $16.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":130609,"source":{"system":"sec-edgar","filing":"0001689375-24-000048","document":"wk-form4_1724186017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000048/wk-form4_1724186017.xml","form_type":"4"}},{"id":1428313,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-08-20T20:33:43.000Z","date":"2024-08-16","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":1.74,"value":34800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024."}],"balance_after":157204,"source":{"system":"sec-edgar","filing":"0001689375-24-000048","document":"wk-form4_1724186017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000048/wk-form4_1724186017.xml","form_type":"4"}},{"id":1587959,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-03-08T21:34:26.000Z","date":"2024-03-06","kind":"sale","planned":true,"acquired":false,"shares":1826,"price":12.3213,"value":22498.6938,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.02 to $12.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":137204,"source":{"system":"sec-edgar","filing":"0001689375-24-000007","document":"wk-form4_1709933649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000007/wk-form4_1709933649.xml","form_type":"4"}},{"id":1599765,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T00:46:00.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":50100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the option shares shall vest and become exercisable on March 1, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully\nvested on March 1, 2028."}],"balance_after":50100,"derivative":{"exercise_price":13.73,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":50100},"source":{"system":"sec-edgar","filing":"0001689375-24-000004","document":"wk-form4_1709685952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000004/wk-form4_1709685952.xml","form_type":"4"}},{"id":1599764,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-03-06T00:46:00.000Z","date":"2024-03-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":1486,"price":12.2788,"value":18246.2968,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":139030,"source":{"system":"sec-edgar","filing":"0001689375-24-000004","document":"wk-form4_1709685952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000004/wk-form4_1709685952.xml","form_type":"4"}},{"id":1599763,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-03-06T00:46:00.000Z","date":"2024-03-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":409,"price":13.3673,"value":5467.2257,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":140516,"source":{"system":"sec-edgar","filing":"0001689375-24-000004","document":"wk-form4_1709685952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000004/wk-form4_1709685952.xml","form_type":"4"}},{"id":1599762,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-03-06T00:46:00.000Z","date":"2024-03-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":343,"price":12.423,"value":4261.089,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $13.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":140925,"source":{"system":"sec-edgar","filing":"0001689375-24-000004","document":"wk-form4_1709685952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000004/wk-form4_1709685952.xml","form_type":"4"}},{"id":1599761,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-03-06T00:46:00.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan.  Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 50% on March 1, 2026 and (ii) the remaining 50% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan.  Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 50% on March 1, 2026 and (ii) the remaining 50% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":141268,"source":{"system":"sec-edgar","filing":"0001689375-24-000004","document":"wk-form4_1709685952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000004/wk-form4_1709685952.xml","form_type":"4"}},{"id":1599760,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2024-03-06T00:46:00.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":33100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan.  Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan.  Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":81268,"source":{"system":"sec-edgar","filing":"0001689375-24-000004","document":"wk-form4_1709685952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937524000004/wk-form4_1709685952.xml","form_type":"4"}},{"id":1788087,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-06T21:07:32.000Z","date":"2023-09-01","kind":"grant","planned":true,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027."}],"balance_after":21500,"derivative":{"exercise_price":15.41,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001689375-23-000061","document":"wf-form4_169403443743456.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000061/wf-form4_169403443743456.xml","form_type":"4"}},{"id":1788086,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-09-06T21:07:32.000Z","date":"2023-09-06","kind":"sale","planned":true,"acquired":false,"shares":59,"price":14.0069,"value":826.4071,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":48168,"source":{"system":"sec-edgar","filing":"0001689375-23-000061","document":"wf-form4_169403443743456.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000061/wf-form4_169403443743456.xml","form_type":"4"}},{"id":1788085,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-09-06T21:07:32.000Z","date":"2023-09-06","kind":"sale","planned":true,"acquired":false,"shares":913,"price":13.4312,"value":12262.6856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.88 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":48227,"source":{"system":"sec-edgar","filing":"0001689375-23-000061","document":"wf-form4_169403443743456.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000061/wf-form4_169403443743456.xml","form_type":"4"}},{"id":1788084,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-09-06T21:07:32.000Z","date":"2023-09-05","kind":"tax_withholding","planned":true,"acquired":false,"shares":436,"price":14.4625,"value":6305.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."}],"balance_after":49140,"source":{"system":"sec-edgar","filing":"0001689375-23-000061","document":"wf-form4_169403443743456.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000061/wf-form4_169403443743456.xml","form_type":"4"}},{"id":1788083,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-09-06T21:07:32.000Z","date":"2023-09-01","kind":"grant","planned":true,"acquired":true,"shares":14200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":49576,"source":{"system":"sec-edgar","filing":"0001689375-23-000061","document":"wf-form4_169403443743456.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000061/wf-form4_169403443743456.xml","form_type":"4"}},{"id":1831184,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-07-12T20:33:27.000Z","date":"2023-07-11","kind":"sale","planned":true,"acquired":false,"shares":3897,"price":18.048,"value":70333.056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":35376,"source":{"system":"sec-edgar","filing":"0001689375-23-000047","document":"wf-form4_168919399033901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000047/wf-form4_168919399033901.xml","form_type":"4"}},{"id":1831183,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-07-12T20:33:27.000Z","date":"2023-07-10","kind":"sale","planned":true,"acquired":false,"shares":3200,"price":18.0016,"value":57605.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":39273,"source":{"system":"sec-edgar","filing":"0001689375-23-000047","document":"wf-form4_168919399033901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000047/wf-form4_168919399033901.xml","form_type":"4"}},{"id":1847209,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-22T20:46:08.000Z","date":"2023-06-22","kind":"sale","planned":true,"acquired":false,"shares":7097,"price":16.0208,"value":113699.6176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42473,"source":{"system":"sec-edgar","filing":"0001689375-23-000042","document":"wf-form4_168746675476462.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000042/wf-form4_168746675476462.xml","form_type":"4"}},{"id":1847208,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-22T20:46:08.000Z","date":"2023-06-20","kind":"sale","planned":true,"acquired":false,"shares":8885,"price":14.9357,"value":132703.6945,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.43 to $15.0090, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":49570,"source":{"system":"sec-edgar","filing":"0001689375-23-000042","document":"wf-form4_168746675476462.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000042/wf-form4_168746675476462.xml","form_type":"4"}},{"id":1917570,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-19T21:46:36.000Z","date":"2023-03-01","kind":"grant","planned":false,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively."}],"balance_after":21500,"derivative":{"exercise_price":12.25,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001689375-23-000026","document":"wf-form4a_168194078070459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000026/wf-form4a_168194078070459.xml","form_type":"4/A","original_submission_date":"2023-03-03"}},{"id":1917569,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-04-19T21:46:36.000Z","date":"2023-03-01","kind":"grant","planned":false,"acquired":true,"shares":14200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively."}],"balance_after":58455,"source":{"system":"sec-edgar","filing":"0001689375-23-000026","document":"wf-form4a_168194078070459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000026/wf-form4a_168194078070459.xml","form_type":"4/A","original_submission_date":"2023-03-03"}},{"id":1976462,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T21:33:14.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027."}],"balance_after":43000,"derivative":{"exercise_price":12.25,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0001689375-23-000012","document":"wf-form4_167787916889742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000012/wf-form4_167787916889742.xml","form_type":"4"}},{"id":1976461,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:33:14.000Z","date":"2023-03-02","kind":"tax_withholding","acquired":false,"shares":1028,"price":11.5962,"value":11920.8936,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."}],"balance_after":72655,"source":{"system":"sec-edgar","filing":"0001689375-23-000012","document":"wf-form4_167787916889742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000012/wf-form4_167787916889742.xml","form_type":"4"}},{"id":1976460,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:33:14.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":28400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":73683,"source":{"system":"sec-edgar","filing":"0001689375-23-000012","document":"wf-form4_167787916889742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937523000012/wf-form4_167787916889742.xml","form_type":"4"}},{"id":2127716,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-02T20:54:42.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":2100,"price":24.0453,"value":50495.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45283,"source":{"system":"sec-edgar","filing":"0001689375-22-000040","document":"wf-form4_166742245826942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000040/wf-form4_166742245826942.xml","form_type":"4"}},{"id":2131312,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:48:02.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":900,"price":21.8544,"value":19668.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.66 to $22.14 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47383,"source":{"system":"sec-edgar","filing":"0001689375-22-000038","document":"wf-form4_166691086621050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000038/wf-form4_166691086621050.xml","form_type":"4"}},{"id":2131311,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:48:02.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":5414,"price":20.9689,"value":113525.6246,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 to $21.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":48283,"source":{"system":"sec-edgar","filing":"0001689375-22-000038","document":"wf-form4_166691086621050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000038/wf-form4_166691086621050.xml","form_type":"4"}},{"id":2131310,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:48:02.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":3034,"price":20.1043,"value":60996.4462,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.51 to $20.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":53697,"source":{"system":"sec-edgar","filing":"0001689375-22-000038","document":"wf-form4_166691086621050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000038/wf-form4_166691086621050.xml","form_type":"4"}},{"id":2133256,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-10-24T21:13:30.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":1302,"price":19.6583,"value":25595.1066,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.33 to $19.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":56731,"source":{"system":"sec-edgar","filing":"0001689375-22-000036","document":"wf-form4_166664590901730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000036/wf-form4_166664590901730.xml","form_type":"4"}},{"id":2133255,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-10-24T21:13:30.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":1102,"price":18.8809,"value":20806.7518,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.30 to $19.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":58033,"source":{"system":"sec-edgar","filing":"0001689375-22-000036","document":"wf-form4_166664590901730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000036/wf-form4_166664590901730.xml","form_type":"4"}},{"id":2133254,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-10-24T21:13:30.000Z","date":"2022-10-21","kind":"sale","acquired":false,"shares":2771,"price":18.285,"value":50667.735,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":59135,"source":{"system":"sec-edgar","filing":"0001689375-22-000036","document":"wf-form4_166664590901730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000036/wf-form4_166664590901730.xml","form_type":"4"}},{"id":2133253,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-10-24T21:13:30.000Z","date":"2022-10-20","kind":"sale","acquired":false,"shares":905,"price":18.0735,"value":16356.5175,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":61906,"source":{"system":"sec-edgar","filing":"0001689375-22-000036","document":"wf-form4_166664590901730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000036/wf-form4_166664590901730.xml","form_type":"4"}},{"id":2150147,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:08:56.000Z","date":"2022-09-26","kind":"sale","acquired":false,"shares":215,"price":16.2477,"value":3493.2555,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":62811,"source":{"system":"sec-edgar","filing":"0001689375-22-000032","document":"wf-form4_166439931631699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000032/wf-form4_166439931631699.xml","form_type":"4"}},{"id":2150146,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:08:56.000Z","date":"2022-09-26","kind":"sale","acquired":false,"shares":1329,"price":15.32,"value":20360.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":63026,"source":{"system":"sec-edgar","filing":"0001689375-22-000032","document":"wf-form4_166439931631699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000032/wf-form4_166439931631699.xml","form_type":"4"}},{"id":2152294,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-23T20:55:53.000Z","date":"2022-09-23","kind":"sale","acquired":false,"shares":1018,"price":15.0694,"value":15340.6492,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":64355,"source":{"system":"sec-edgar","filing":"0001689375-22-000029","document":"wf-form4_166396653628463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000029/wf-form4_166396653628463.xml","form_type":"4"}},{"id":2152293,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-23T20:55:53.000Z","date":"2022-09-21","kind":"sale","acquired":false,"shares":3275,"price":15.1258,"value":49536.995,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":65373,"source":{"system":"sec-edgar","filing":"0001689375-22-000029","document":"wf-form4_166396653628463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000029/wf-form4_166396653628463.xml","form_type":"4"}},{"id":2156560,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-19T20:34:16.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":100,"price":15.01,"value":1501.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."}],"balance_after":68648,"source":{"system":"sec-edgar","filing":"0001689375-22-000027","document":"wf-form4_166361963989994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000027/wf-form4_166361963989994.xml","form_type":"4"}},{"id":2161680,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-12T20:14:33.000Z","date":"2022-09-09","kind":"sale","acquired":false,"shares":865,"price":15.0646,"value":13030.879,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":68748,"source":{"system":"sec-edgar","filing":"0001689375-22-000018","document":"wf-form4_166301365870769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000018/wf-form4_166301365870769.xml","form_type":"4"}},{"id":2161679,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-12T20:14:33.000Z","date":"2022-09-08","kind":"sale","acquired":false,"shares":912,"price":15.1472,"value":13814.2464,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":69613,"source":{"system":"sec-edgar","filing":"0001689375-22-000018","document":"wf-form4_166301365870769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000168937522000018/wf-form4_166301365870769.xml","form_type":"4"}},{"id":2166566,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-06T20:32:24.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":5632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":70525,"source":{"system":"sec-edgar","filing":"0001104659-22-097873","document":"tm2225276-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000110465922097873/tm2225276-4_4seq1.xml","form_type":"4"}},{"id":2213227,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-06T20:18:17.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":33788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares shall vest and become exercisable on July 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on July 1, 2026."}],"balance_after":33788,"derivative":{"exercise_price":12,"expiration_date":"2032-07-01","underlying":"Common stock","underlying_shares":33788},"source":{"system":"sec-edgar","filing":"0001104659-22-077707","document":"tm2220515-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000110465922077707/tm2220515-3_4seq1.xml","form_type":"4"}},{"id":2219642,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-06-29T20:02:52.000Z","date":"2022-06-27","kind":"sale","acquired":false,"shares":7714,"price":13,"value":100282.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022."}],"balance_after":64893,"source":{"system":"sec-edgar","filing":"0001104659-22-075788","document":"tm2220048-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000110465922075788/tm2220048-2_4seq1.xml","form_type":"4"}},{"id":2357226,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:11:06.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":67575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026."}],"balance_after":67575,"derivative":{"exercise_price":11.57,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":67575},"source":{"system":"sec-edgar","filing":"0001104659-22-030009","document":"tm228284-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000110465922030009/tm228284-5_4seq1.xml","form_type":"4"}},{"id":2357225,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:11:06.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":11263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":72607,"source":{"system":"sec-edgar","filing":"0001104659-22-030009","document":"tm228284-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000110465922030009/tm228284-5_4seq1.xml","form_type":"4"}},{"id":2531203,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-01T22:58:29.000Z","date":"2021-10-28","kind":"grant","acquired":true,"shares":95148,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 48 equal monthly installments commencing on October 28, 2021 (the \"Vesting Start Date\"), such that the option shares shall be fully vested on the four-year anniversary of the Vesting Start Date."}],"balance_after":95148,"derivative":{"exercise_price":20,"expiration_date":"2031-10-28","underlying":"Common stock","underlying_shares":95148},"source":{"system":"sec-edgar","filing":"0001104659-21-132476","document":"tm2131250-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000110465921132476/tm2131250-17_4seq1.xml","form_type":"4"}}]}